Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)
Status:
Completed
Trial end date:
2018-01-30
Target enrollment:
Participant gender:
Summary
This study will be conducted to demonstrate, using polysomnography, that lemborexant 10
milligrams (mg) and 5 mg is superior to placebo on objective sleep onset as assessed by
latency to persistent to sleep (LPS) after the last 2 nights of 1 month of treatment in
participants 55 years and older with insomnia disorder.